Navigation Links
China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
Date:5/26/2009

HARBIN, China, May 26 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that it recently obtained production approval from the State Food and Drug Administration (SFDA) in China for two of its newly developed drugs.

Acyclovir gel is used to treat the skin infection due to varicella-zoster virus and the herpes simplex virus. Shuanghuanglian suppositories helps relieve cold and flu symptoms such as fever, cough and sore throat pain. It can also be used to treat upper respiratory infections and pneumonia. Both of the products are for common diseases, and should benefit as a result of the rapidly expanded rural health market, especially after China's recent reform of the insurance system. They will be introduced to the market in the third quarter of 2009.

China Sky One Medical started R&D of the two drugs in 2003 and submitted the applications for SFDA approval in early 2007. The document numbers for the drugs are H20093399 and Z20093134. In all, China Sky One Medical has received production approval for 25 products since January 2008, including six new products in 2009. Currently, the Company has over 20 products in the application process under SFDA review.

Recently the Company also received the approval from SFDA for Diclofenac Sodium suppositories to enter the clinical trial, with the document number 2009L02108. This drug is used to treat rheumatoid arthritis and to relieve pain after operations and fever.

"We are excited about our new drug approvals, which are a testament to our outstanding R&D capability and our understanding of the pharmaceutical market in China," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We will continue to develop exciting new products in the future and are committed to increasing our pipeline and R&D capabilities."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
2. The Hamner Institutes Announce Partnership With China Medical City
3. China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a SOX 404 Compliance Program
4. Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China
5. China Biologic Products Announces Strong First Quarter 2009 Results
6. China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results
7. China Biologic Products Announces 2009 First Quarter Results Conference Call
8. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
9. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
10. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
11. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 - New FDA action date of ... FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast has ... indicated for the treatment of signs and symptoms of dry eye ... potential to be the only product approved in the U.S. in the past decade indicated ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments will showcase ... demos and poster sessions, and present on the analysis of mycotoxins and medical ... 6 to 10 at the Georgia World Congress Center in Atlanta, Georgia. ...
(Date:2/4/2016)... 4, 2016 Beike Biotechnology, the ... attended a ceremony in late 2015 to mark their ... in 2016. --> --> ... for Personalized Cell Therapy" was hosted by the Shenzhen ... both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... Columbia and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused ... announced that it will present at the 18 th ... February 8, 2016 at 10:00 a.m. EST in ... , DelMar,s president and CEO, will provide an update on ...
Breaking Biology Technology:
(Date:1/22/2016)... DUBLIN , Jan. 22, 2016 /PRNewswire/ ... announced the addition of the "Global ... report to their offering. --> ... of the "Global Biometrics Market in ... offering. --> Research and ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/11/2016)...  higi, the leading retail and omni-channel community engagement ... and mobile, today announced it has closed funding ... --> --> ... higi,s health platform – its network of health ... expanding services and programs to retail partners and ...
Breaking Biology News(10 mins):